Evidence map›Paper›PMID 33525579›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans.

Esther Papaseit, Eulalia Olesti, Clara Pérez-Mañá, Marta Torrens, Francina Fonseca, Marc Grifell, Mireia Ventura, Rafael de la Torre, Magí Farré

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Esther PapaseitClinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTP-IGTP), 08916 Badalona, Spain.
Eulalia OlestiIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, Hospital del Mar Medical Research Institute (IMIM) and Universitat Pompeu Fabra (CEXS-UPF), 08003 Barcelona, Spain.
Clara Pérez-MañáClinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTP-IGTP), 08916 Badalona, Spain.ORCID 0000-0001-6343-6918
Marta TorrensDepartment of Psychiatry and Forensic Medicine, Institut de Neuropsiquiatria i Adiccions (INAD), Universitat Autònoma de Barcelona (UAB), 08003 Barcelona, Spain.ORCID 0000-0001-6222-4761
Francina FonsecaDepartment of Psychiatry and Forensic Medicine, Institut de Neuropsiquiatria i Adiccions (INAD), Universitat Autònoma de Barcelona (UAB), 08003 Barcelona, Spain.ORCID 0000-0002-0779-6545
Marc GrifellDepartment of Psychiatry and Forensic Medicine, Institut de Neuropsiquiatria i Adiccions (INAD), Universitat Autònoma de Barcelona (UAB), 08003 Barcelona, Spain.
Mireia VenturaEnergy Control, Associació Benestar i Desenvolupament, 08041 Barcelona, Spain.
Rafael de la TorreIntegrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, Hospital del Mar Medical Research Institute (IMIM) and Universitat Pompeu Fabra (CEXS-UPF), 08003 Barcelona, Spain.ORCID 0000-0002-6765-1866
Magí FarréClinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol (HUGTP-IGTP), 08916 Badalona, Spain.ORCID 0000-0001-8338-7543
Universitat Autònoma de Barcelona · ESUniversitat Pompeu Fabra · ES

Funding

AGAUR Gencat Suport Grups de Recerca 2017 SGR 316Instituto de Salud Carlos III FIS PI14/00715, FIS PI17/01962, RD16/0017/0003,Ministerio de Sanidad, Política Social e Igualdad (Plan Nacional sobre Drogas-PNSD) 2015I054The European Commission (Predicting Risk of Emerging Drugs with In silico and Clinical Toxicology (PREDICT) HOME/2014/JDRU/AG/DRUG/7082
6 · The paper itself

Abstract

Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic conditions. An observational study was conducted to assess and compare the acute pharmacological effects, as well as the oral fluid (saliva) concentrations of mephedrone self-administered orally and intranasally. Ten healthy experienced drug users (4 females and 6 males) self-administered a single dose of mephedrone, orally (

Indexed as

cathinones bath saltsintranasal administrationmephedrone (4-methylmethcathinone)novel psychoactive substances (NPS)oral administrationpsychostimulants

Identifiers

PMID33525579
PMCPMC7912650
OpenAlexW3123817871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.